Open AccessDid brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?
Author(s) -
Mehdi Hamadani
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.280284
Subject(s) - brentuximab vedotin , oncology , medicine , reed–sternberg cell , hodgkin lymphoma , lymphoma
Not available.